Canadian Cardiovascular Society

Program Announcement for Annual ASPC Congress on CVD Prevention July 2023

Retrieved on: 
Thursday, May 25, 2023
The American Journal of Cardiology, Abstract, Canadian Cardiovascular Society, Atrial fibrillation, MasterClass, Award, Cardiovascular disease, Stanford University, Emory University, British Cardiovascular Society, EAPC, Imaging, ASPC, CDC, Boston University School of Public Health, Pioneer, Congress, Baylor University, American Journal, Live, Cardiology, CCS, European Association for Cardio-Thoracic Surgery, ESC, European Society of Cardiology, Society, Hearts, Medical device, Heart

JACKSONVILLE, Fla., May 25, 2023 /PRNewswire/ -- The American Society for Preventive Cardiology announces details of a full program of events to be held at their annual Congress on Cardiovascular Disease Prevention, scheduled in 2023 for July 19-23 hosted at the Live! By Loews hotel in Arlington, TX.

Key Points: 
  • JACKSONVILLE, Fla., May 25, 2023 /PRNewswire/ -- The American Society for Preventive Cardiology announces details of a full program of events to be held at their annual Congress on Cardiovascular Disease Prevention, scheduled in 2023 for July 19-23 hosted at the Live!
  • Featured in the 2023 expanded program are diverse content with many international experts joining the program.
  • The Pioneer in Prevention Award will be presented to Dr. Larry Sperling from Emory university and the CDC's Million Hearts program.
  • ASPC is looking forward to honoring these Awardees during the opening session of the Congress on Friday, July 21 from 10:00 – 11:35 AM.

BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure

Retrieved on: 
Tuesday, March 22, 2022
CCS, Company, Cell, IDE, Heart, Therapy, NYHA, Transplant, Forward-looking statement, Bone marrow, BCDA, CMS, Hospital, Centers for Medicare & Medicaid Services, Patient, Probability, Heart failure, U.S. Securities and Exchange Commission, New York Heart Association Functional Classification, Canadian Cardiovascular Society, Center for Medicare and Medicaid Innovation, Learning, NK1R, Safety, Center, Nasdaq, GLOBE, Medicare, Helix, FDA, Cell therapy, Security (finance), Pharmaceutical industry, Medical imaging

This new CMS code to be submitted by hospitals performing the CardiAMP cell therapy procedure is available April 1, 2022.

Key Points: 
  • This new CMS code to be submitted by hospitals performing the CardiAMP cell therapy procedure is available April 1, 2022.
  • The code provides clear reimbursement for the study procedure performed for both the treatment and control arms for the ongoing cell therapy pivotal trials in two cardiovascular indications: the CardiAMP Cell Therapy Heart Failure Trial (NCT02438306) and the CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial (NCT03455725).
  • Further, it provides additional clarity of CMS financial support for institutions conducting the CardiAMP Cell Therapy Heart Failure Trial and CardiAMP Chronic Myocardial Ischemia Trials.
  • The CardiAMP Cell Therapy Heart Failure Trial has been supported financially by the Maryland Stem Cell Research Fund and the Center for Medicare and Medicaid Services.

Novartis Canada launches the Biome Summit -- a catalyst to healthcare transformation and the future of care systems in Canada

Retrieved on: 
Thursday, August 26, 2021
Patient, Biome, Stroke, Degenerative disease, Amazon Web Services, Health care, Program, Love, CCS, Conditional sentence, Diabetes, Chair, Shoppers Drug Mart, Government, Hope, Disease, Person, Health, Canadian Organization for Rare Disorders, Dean (education), Awareness, Organization, Canadian Cardiovascular Society, Hospital, Learning, List of life sciences, Mortality, Summit, Partnership, Solution, CHPA, CEO, Novartis, Map, Education, Diabetes Canada, AWS, Cardiovascular disease, Department, Heart failure, Infarction, Medical device, Pharmaceutical industry, Medicine

By leveraging the power of partnerships to raise awareness for cardiovascular disease, the Biome Summit will ultimately create a blueprint for long-term cardiovascular healthcare transformation.

Key Points: 
  • By leveraging the power of partnerships to raise awareness for cardiovascular disease, the Biome Summit will ultimately create a blueprint for long-term cardiovascular healthcare transformation.
  • The Biome Summit builds on the intent and purpose of the company's Biome Innovation Hub, which Novartis launched in Canada last fall.
  • Novartis is partnering with C2 International, convener of communities both online and in-person, to produce the Biome Summit series.
  • The Biome Summit will bring together healthcare professionals, patient organizations, government, and private organizations to discuss, debate and drive real solutions.

Neovasc Announces Submission of COSIRA-II Protocol Supplement to FDA

Retrieved on: 
Tuesday, August 17, 2021
Adrenal insufficiency, Blood, Intention, European Union, Food, Health, Hospital, Indian stock exchange, Safety, Risk, Christ Hospital, Canadian Cardiovascular Society, Union, Conversation, OH, Heart, Forward-looking statement, History, Sale, Regulation of tobacco by the U.S. Food and Drug Administration, Industry, Muscle tissue, Regulatory affairs, Legislation, Analysis, Incidence, Insurance, Canadian Cardiovascular Society grading of angina pectoris, Nasdaq, Perfusion, Angina, FDA, Company, European Heart Journal, Growth, Literature, GLOBE, CCS, Physician, Private Securities Litigation Reform Act, Marketing, Management, News, Patient, IDE, TSX, COVID-19, Pharmaceutical industry, Medical device

(Neovasc or the Company) ( Nasdaq , TSX : NVCN) announced today that it has filed a supplement to the COSIRA-II Investigational Device Exemption (IDE) Study with the U.S. Food and Drug Administration (FDA).

Key Points: 
  • (Neovasc or the Company) ( Nasdaq , TSX : NVCN) announced today that it has filed a supplement to the COSIRA-II Investigational Device Exemption (IDE) Study with the U.S. Food and Drug Administration (FDA).
  • The proposed primary endpoint of the trial is change in exercise tolerance testing time via a modified Bruce protocol between baseline and 6-month follow-up.
  • The study is planned to enroll approximately 380 patients at up to 50 sites primarily in the United States.
  • (1) Submission of the IDE Supplement is an important step as we work towards commencing the trial this year.

Neovasc Comments on EuroIntervention Article

Retrieved on: 
Monday, April 19, 2021
Canadian Cardiovascular Society, Angina, XC2, CCS, Cardiology, Medicine, Clinical medicine, Canadian Cardiovascular Society grading of angina pectoris

Angina severity reflected by the Canadian Cardiovascular Society (CCS) grading improved from a mean of 3.2\xc2\xb10.5 to 1.6\xc2\xb10.8, (p

Key Points: 
  • Angina severity reflected by the Canadian Cardiovascular Society (CCS) grading improved from a mean of 3.2\xc2\xb10.5 to 1.6\xc2\xb10.8, (p
  • Only very limited differences in anti-anginal medications were recorded, with a mean of 1.9\xc2\xb11.1 drugs per patient at baseline vs 1.8\xc2\xb11.1 at follow-up (p=0.77).
  • Prof. Stefan Verheye, M.D., PhD, Antwerp Cardiovascular Center Middelheim, Antwerp, Belgium, said, \xe2\x80\x9cIt is reassuring to see the consistent improvements in chest pain in patients treated with the Reducer.
  • It affects millions of patients worldwide, who typically lead severely restricted lives as a result of their disabling symptoms, and its incidence is growing.